https://charts.traderzeitung.de/phases/CA23256X4075 string(1494) "{"isin":"CA23256X4075","name":"Helus Pharma Inc","stock_id_xnas":122418937,"stock_id_xnys":null,"generated_at":"2026-09-24 01:33:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":12.96,"close_at":"2026-09-21 15:28:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":13.65,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":5.3241},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":14.05,"close_at":"2026-09-22 00:30:00","complete":true,"perf_pct":2.9304}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":13.83,"close_at":"2026-09-22 15:26:00","complete":true,"perf_pct":-1.5658},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":13.68,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":-1.0846},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":13.66,"close_at":"2026-09-23 15:05:00","complete":true,"perf_pct":-0.1462},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":13.02,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-4.6852},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":13.02,"close_at":"2026-09-23 23:57:00","complete":false,"perf_pct":0}]}]}"

Cybin Aktie News & Nachrichten

[WKN: A40NJY | Symbol: HELP]

Realtimekurs

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.